Additionally, it has been demonstrated that luteolin lowers nuclear factor erythroid 2-related factor 2 (Nrf2)-driven activation and prevents STAT3 from making human breast cancer MDA-MB-231 cells more vulnerable to the drugs doxorubicin and paclitaxel [115]. Here, NFE2L2 is linked to breast cancer.